Ovarian steroid cell tumor with biallelic adenomatous polyposis coli inactivation in a patient with familial adenomatous polyposis by Hu, Patrick J. et al.
GENES, CHROMOSOMES & CANCER 51:283–289 (2012)
Ovarian Steroid Cell Tumor with Biallelic
Adenomatous Polyposis Coli Inactivation in a
Patient with Familial Adenomatous Polyposis
Patrick J. Hu,1,2,3,4*† Stewart M. Knoepp,2,5† Rong Wu,5 and Kathleen R. Cho1,2,5
1Departmentof Internal Medicine,Universityof Michigan Medical School,Ann Arbor,MI
2Universityof Michigan Comprehensive Cancer Center,Ann Arbor,MI
3Life Sciences Institute,Universityof Michigan,Ann Arbor,MI
4Departmentof Cell and Developmental Biology,Universityof Michigan Medical School,Ann Arbor,MI
5Departmentof Pathology,Universityof Michigan Medical School,Ann Arbor,MI
Familial adenomatous polyposis (FAP) is an autosomal dominant cancer predisposition syndrome that accounts for approxi-
mately 0.5–1% of all colorectal cancer cases. It is caused by germline mutations in the gene encoding the adenomatous pol-
yposis coli (APC) tumor suppressor. Somatic APC inactivation due to mutation or loss of heterozygosity (LOH) promotes
the development of adenomatous polyps by stabilizing the transcriptional coactivator b-catenin. Although colorectal cancer
is by far the most common malignancy seen in FAP patients, the widespread use of prophylactic colectomy in these
patients has increased the clinical importance of extracolonic tumors that are part of the neoplastic spectrum in FAP.
Many of these tumors exhibit LOH or somatic APC mutation, strongly supporting a causative role of APC inactivation in
their pathogenesis. Here we describe a 47-year-old female FAP patient with clinical manifestations of virilization who was
found to have an ovarian steroid cell tumor, a rare neoplasm not known to be associated with FAP. Immunohistochemical
analysis of the ovarian tumor demonstrated strong nuclear b-catenin staining consistent with somatic APC inactivation, and
molecular analysis conﬁrmed biallelic APC inactivation in the tumor. Our ﬁndings provide the ﬁrst evidence that ovarian
steroid cell tumors may be an extracolonic manifestation of FAP and implicate b-catenin activation as an oncogenic mecha-
nism in ovarian steroid cell tumorigenesis. VC 2011 Wiley Periodicals, Inc.
INTRODUCTION
Familial adenomatous polyposis (FAP) is an
autosomal dominant cancer predisposition syn-
drome characterized by extensive colorectal poly-
posis and early-onset colorectal cancer. FAP is
caused by germline mutations that result in trun-
cation of the adenomatous polyposis coli (APC)
tumor suppressor protein (Groden et al., 1991;
Nishisho et al., 1991). Wild-type APC acts in the
Wnt signaling pathway to regulate cell prolifera-
tion and differentiation, primarily by binding to
and promoting the degradation of the transcrip-
tional coactivator b-catenin (Aoki and Taketo,
2007). Somatic inactivation of the wild-type APC
allele is thought to promote colorectal polyposis
in FAP patients by stabilizing b-catenin and con-
stitutively activating b-catenin/TCF4 transcrip-
tional complexes (Korinek et al., 1997; Morin
et al., 1997). Mutation of the wild-type APC allele
in the majority of colorectal adenomas in FAP
patients indicates that APC inactivation is a criti-
cal early event in the pathogenesis of colorectal
cancer in FAP patients (Miyoshi et al., 1992;
Miyaki et al., 1994). Although FAP only accounts
for 0.5–1% of all colorectal cancer cases (Half
et al., 2009; Fearon, 2011), the pathophysiologic
underpinnings of FAP have proven to be highly
relevant to sporadic colorectal cancers, the major-
ity of which harbor mutations that activate Wnt
signaling (Segditsas and Tomlinson, 2006).
FAP is associated with a variety of extracolonic
tumors. Compared with the general population,
FAP patients are at increased risk of developing
desmoid tumors, hepatoblastoma, and tumors of
the upper gastrointestinal tract, thyroid gland,
brain, pancreas, and adrenal glands (Marchesa
et al., 1997; Smith et al., 2000; Shah and Lindor,
2010). The demonstration that both APC alleles
are frequently mutated in these extracolonic
yPatrick J. Hu and Stewart M. Knoepp contributed equally to
this work.
Supported by: American Cancer Society Research Scholar
Grant number: RSG-10-132-01-DDC.
*Correspondence to: Patrick J. Hu, 6403 LSI, 210 Washtenaw
Avenue, Ann Arbor, MI 48109-2216. E-mail: pathu@umich.edu
Received 11 August 2011; Accepted 18 October 2011
DOI 10.1002/gcc.20953
Published online 15 November 2011 in
Wiley Online Library (wileyonlinelibrary.com).
VC 2011 Wiley Periodicals, Inc.
tumors (Miyaki et al., 1993, 2000; Hamilton
et al., 1995; Kurahashi et al., 1995; Wakatsuki
et al., 1998; Abraham et al., 2000, 2001; Groves
et al., 2002; Blaker et al., 2004; Hosogi et al.,
2009; Gaujoux et al., 2010) suggests that APC
inactivation is critical to the pathogenesis of most
if not all tumors to which FAP patients are
predisposed.
Although colorectal cancer has historically been
the major cause of death in FAP patients, the
routine incorporation of prophylactic colectomy
into the clinical management of FAP patients has
drastically reduced colorectal cancer-related mor-
tality in this population. This has resulted in a
concomitant increase in the morbidity and mor-
tality associated with extracolonic neoplasms
known to be associated with FAP (Bertario et al.,
1994; Belchetz et al., 1996; Galle et al., 1999).
Therefore, characterizing the full spectrum of
FAP-associated neoplasms and understanding
their pathogenesis has become increasingly im-
portant to the clinical management of FAP
patients.
Here we describe an FAP patient with an ovar-
ian steroid cell tumor exhibiting nuclear b-cate-
nin localization and biallelic inactivation of APC.
This report provides the ﬁrst evidence that ovar-
ian steroid cell tumors are part of the FAP neo-
plastic spectrum and implicates dysregulation of
Wnt signaling in the pathogenesis of ovarian ste-
roid cell tumors.
MATERIALS AND METHODS
This study was reviewed by the Institutional
Review Board at the University of Michigan
Medical School and designated as exempt. Tissue
samples were prepared utilizing standard formalin
ﬁxation followed by automated dehydration and
parafﬁn-embedding, resulting in formalin-ﬁxed
parafﬁn-embedded (FFPE) tissue. Sections for
light microscopy were stained with hematoxylin
and eosin (H&E). Immunohistochemistry (IHC)
was performed on unstained FFPE tissue using a
Ventana Autostainer (Ventana Medical Systems,
Tucson, AZ). Incubation with a mouse monoclo-
nal antibody directed against b-catenin (1/50 dilu-
tion; BD Biosciences, San Jose, CA) was
performed for 32 min after antigen retrieval with
CC2 buffer (pH 6.0) at 91

C for 24 min. Incuba-
tion with a mouse monoclonal antibody directed
against inhibin (prediluted; Ventana Medical Sys-
tems) was performed for 28 min after antigen
retrieval for 24 min with CC1M buffer (pH 8.5)
at 95

C for 24 min. Positive and negative controls
were performed in parallel. Slides were reviewed
and diagnosed by consensus of two pathologists
(SK and KC) in conjunction with a pathology
multidisciplinary consensus conference.
APC and CTNNB1 Sequence Analysis
Genomic DNA was extracted from FFPE tis-
sue sections using standard techniques. Brieﬂy,
sections were deparafﬁnized in xylene, then rehy-
drated through graded ethanols and water. Unde-
sired areas of tissue were manually
microdissected off the sections using H&E-
stained sections as dissection guides. Remaining
tissues were scraped into 1.5 ml tubes and incu-
bated with Gentra Puregene cell lysis solution
(Qiagen, Valencia, CA) and DNA extraction was
carried out according to the manufacturer’s proto-
col. The entirety of CTNNB1 exon 3 was ampli-
ﬁed using a forward primer in exon 2
(CGTGGACAATGGCTACTCAA) and reverse
primer in exon 4 (TGCATACTGTCCATC
AATA). The PCR products were sequenced en
masse using a primer in exon 3 (GGAGTTGGA
CATGGCCATGGAA). A DNA fragment encom-
passing the subject’s known germline APC dele-
tion (3927-3931del AAAGA) was ampliﬁed using
forward primer (GATGAAATAGGATGTAATC
AGACG) and reverse primer (TCTGCTGGA
TTTGGTTCTAGG). The APC PCR products
from tumor and non-neoplastic (fallopian tube)
tissues were sequenced en masse. In addition,
APC PCR products were gel puriﬁed (Geneclean
III kit, MP Biomedicals, LLC, OH) and cloned
into the Zero blunt TOPO vector (Invitrogen,
Carlsbad, CA). Individual clones (11 clones from
each tissue sample) were selected and sequenced
using SP6 primers. Sanger sequencing was per-
formed by the University of Michigan’s DNA
Sequencing Core.
Case Report
A 47-year-old woman with FAP was seen
recently for evaluation of an adenocarcinoma at
her ileostomy site. She was diagnosed with FAP
in 1982, when she was found to have colorectal
polyposis and a rectal adenocarcinoma. At that
time she underwent complete proctocolectomy
with end ileostomy. Last year she noted the de-
velopment of a friable growth at her ileostomy
site. Histopathologic analysis of the excised
growth revealed an invasive adenocarcinoma
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arising within a tubulovillous adenoma. Postoper-
atively the growth recurred, and she was seen in
clinic for further management recommendations.
Past medical history was remarkable for gastric
polyps identiﬁed on esophagogastroduodenoscopy
4 years ago. She had a total thyroidectomy in 1994.
Family history was remarkable for a 56-year-old
maternal half-brother with numerous colonic pol-
yps diagnosed at age 46 and a 55-year-old maternal
half-brother with a history of gastric polyps as an
infant. Her mother died 3 years ago of complica-
tions from lymphoma. Physical exam was remark-
able for morbid obesity and hirsutism. Androgen
levels were not measured. Molecular analysis of a
peripheral blood specimen revealed the presence
of a ﬁve-nucleotide deletion within the mutation
cluster region of exon 15 of the APC gene (3927-
3931delAAAGA) resulting in a frameshift at amino
acid position 1309 and subsequent premature ter-
mination codon at amino acid position 1312.
Esophagogastroduodenoscopy revealed no
abnormalities. Balloon-assisted lower enteroscopy
showed multiple sessile polyps, biopsies of which
revealed adenoma. Computed tomography of the
chest, abdomen, and pelvis with intravenous and
oral contrast demonstrated the presence of multi-
ple left adrenal nodules and a 3.5  2.8 cm right
adnexal mass. The largest adrenal nodule and the
adnexal mass exhibited increased 2-deoxy-2-
(18F)ﬂuoro-D-glucose (FDG) avidity on positron
emission tomography. Core biopsy of the left ad-
renal mass revealed cortical adenoma (Fig. 1C).
The patient subsequently underwent resection of
the distal small bowel and the ileostomy as well
as right salpingo-oophorectomy.
RESULTS
Gross examination of the right ovary revealed a
symmetrically enlarged 4.3 cm ovary with a
smooth surface. The fallopian tube was unre-
markable. Sectioning of the ovary revealed pre-
dominant replacement with two well-
circumscribed tan-pink nodules separated by a
thin ﬁbrous band. Focal hemorrhage was present
in both nodules.
On microscopic examination, the tumor con-
sisted predominantly of a diffuse pattern of
rounded cells with distinct borders and moderate
to abundant eosinophilic cytoplasm (Figs. 1A and
Figure 1. b-catenin immunohistochemistry (IHC). A, B: Ovarian
steroid cell tumor showing (A) cells with eosinophilic cytoplasm
(H&E, 3400) and (B) b-catenin IHC demonstrating diffuse nuclear
and cytoplasmic staining (3400). C,D: Adrenocortical adenoma
showing (C) cells with eosinophilic cytoplasm arranged in cords and
ribbons (H&E, 3400) and (D) b-catenin IHC revealing a membranous
staining pattern (3400).
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2D). Focally the tumor cells were separated by
bands of ﬁbrous stroma (Fig. 2A), showed cyto-
plasmic clearing (Fig. 2B), or showed stromal hya-
linization (Fig. 2C). Tumor cell nuclei showed
distinct but small nucleoli with granular chromatin
(Fig. 2D). Reinke crystals were not present and
mitotic activity was negligible. The cytomorpho-
logic features are consistent with a steroid cell
tumor, not otherwise speciﬁed. The tumor cells
lacked any cytomorphologic features suggestive of
a granulosa cell tumor (i.e., angulated nuclei,
nuclear grooves, mitoses, or high nuclear-to-cyto-
plasmic ratio). Features suggestive of malignancy
(i.e., mitotic activity above 2/high-powered ﬁeld,
necrosis, nuclear atypia, or tumor size greater than
7 cm (Hayes and Scully, 1987) were not observed.
Immunohistochemical staining for b-catenin
showed a strong, diffuse pattern of staining in
nuclei and cytoplasm (Fig. 1B). Intervening endo-
thelial cells from vasculature did not show b-cate-
nin staining (Fig. 1B). An immunostain for inhibin
showed focal granular cytoplasmic staining but
was negative in most tumor cells (data not shown).
H&E staining of a core biopsy specimen
obtained from the FDG-avid left adrenal nodule
showed a characteristic heterogeneity to tumor
cell nuclei ranging from uniform cells with eosin-
ophilic cytoplasm arranged in a corded, trabecular
pattern with delicate vasculature (Fig. 1C) to
more diffuse sheets of cells with pale-staining,
lipid-rich cytoplasm (data not shown). Neither
nuclear enlargement nor pleomorphism was pres-
ent. Immunohistochemical staining for b-catenin
showed a diffuse membranous staining pattern
without nuclear accumulation (Fig. 1D) distinct
from the pattern seen in the ovarian tumor (Fig.
1B).
The prominent nuclear localization of b-cate-
nin seen in the ovarian tumor but not in the adre-
nal tumor (compare Fig. 1B and D) is consistent
with the possibility that the wild-type APC allele
was speciﬁcally mutated or lost in the ovarian tu-
mor. To test this possibility, the region of the
APC gene ﬂanking the exon 15 germline muta-
tion was PCR-ampliﬁed from genomic DNA iso-
lated from both adrenal and ovarian tumors as
well as from non-neoplastic tissue from the fallo-
pian tube. Sequencing of PCR products con-
ﬁrmed the presence of both wild-type and
mutated APC alleles in both fallopian tube and
Figure 2. Ovarian steroid cell tumor, not otherwise speciﬁed. A: Tumor cells with focal separation by
ﬁbrous stroma (H&E stain, 340). B: Diffuse nest of tumor cells with eosinophilic to focally clear cyto-
plasm (H&E stain, 3200). C: Hyalinized area of tumor (H&E stain, 3200). D: Characteristic round to
polygonal cells with eosinophilic cytoplasm and distinct cell borders (H&E stain, 31,000).
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adrenal tumor samples (Fig. 3). Notably, APC
sequences from the ovarian tumor sample sug-
gested the presence of reduced amounts of wild-
type APC compared with mutant APC (Fig. 3B).
To conﬁrm this, PCR products from fallopian
tube and ovarian tumor samples were cloned, and
eleven cloned inserts derived from each template
were sequenced. As expected, half of the fallo-
pian tube clones were wild-type (5/11). In con-
trast, nine of eleven clones from the ovarian
tumor contained the germline deletion. This is
consistent with somatic loss of the wild-type APC
allele in the ovarian tumor. The small amount of
wild-type DNA ampliﬁed from this tumor (Fig.
3B) is likely due to the presence of non-neoplas-
tic cells (e.g., stromal, endothelial and inﬂamma-
tory) within the tumor (Fig. 2).
In colorectal cancers with wild-type APC, b-cat-
enin can be activated by point mutations in exon
3 that alter conserved phosphorylation sites
required for its downregulation by glycogen syn-
thase kinase-3b [GSK-3b; (Ilyas et al., 1997;
Morin et al., 1997)]. To rule out the possibility
that the nuclear localization of b-catenin in
the ovarian tumor was a consequence of somatic
b-catenin mutations in exon 3, exon 3 was
PCR-ampliﬁed from genomic DNA isolated from
fallopian tube, ovarian tumor, and adrenal tumor
samples and sequenced. All three samples
revealed wild-type sequence (Fig. 4). Taken
together, these data strongly suggest that the
nuclear localization of b-catenin in the ovarian
tumor is a consequence of somatic loss of the
wild-type APC allele.
DISCUSSION
Elucidation of the molecular basis of FAP has
led to improvements in the early diagnosis and
prevention of colorectal cancer in FAP patients.
The resultant increase in their survival will likely
lead to the discovery of FAP-associated tumors
not previously known to be part of the spectrum
of neoplasms seen in FAP. An awareness of this
growing spectrum is critical to the optimal clinical
management of these patients.
Here we report for the ﬁrst time an association
between ovarian steroid cell tumor and FAP. In
spite of the fact that ovarian steroid cell tumors
have not previously been reported in FAP
patients, our molecular analysis strongly supports
the inclusion of ovarian steroid cell tumor as an
Figure 3. APC sequences ampliﬁed from genomic DNA isolated from patient tumor specimens. A:
Wild-type and germline mutant APC clones demonstrating the presence of the 3927-3931delAAAGA
mutation. Nucleotides in the wild-type allele that are deleted in the mutant allele are underlined. B:
Sequences of APC PCR products ampliﬁed from genomic DNA isolated from normal fallopian tube, ovar-
ian steroid cell tumor, and adrenal core biopsy specimens.
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extracolonic manifestation of FAP. Immunohisto-
chemical analysis with anti-b-catenin antibodies
clearly demonstrates increased b-catenin levels
and nuclear localization in tumor cells compared
with cells outside of the tumor (Fig. 1B). This is
consistent with somatic inactivation of APC in the
ovarian tumor and is corroborated by molecular
evidence of biallelic APC inactivation in the ovar-
ian tumor (Fig. 3). Both of these ﬁndings are
characteristic of tumors that are established
extracolonic manifestations of FAP (Miyaki et al.,
1993, 2000; Hamilton et al., 1995; Kurahashi et al.,
1995; Wakatsuki et al., 1998; Abraham et al., 2000,
2001; Groves et al., 2002; Hosogi et al., 2009;
Gaujoux et al., 2010).
The benign nature of the ovarian tumor in this
patient is consistent with the association of FAP
with benign lesions in several extracolonic tissues
(Miyaki et al., 1993; Wakatsuki et al., 1998; Abra-
ham et al., 2000; Blaker et al., 2004; Hosogi
et al., 2009; Gaujoux et al., 2010). Notably, condi-
tional expression of a dominant stable b-catenin
mutant in ovarian granulosa cells induces the de-
velopment of benign vascularized follicular
lesions that evolve into granulosa cell tumors.
Whereas b-catenin is expressed in nearly all of
the neoplastic cells in these specimens, immuno-
histochemical analysis revealed that nuclear
b-catenin was generally more prominent in the
premalignant lesions than in the granulosa cell
tumors (Boerboom et al., 2005). This observation
provides additional support for the idea that APC
inactivation and the subsequent stabilization of
b-catenin are early events in carcinogenesis.
Although somatic APC mutations have been
identiﬁed in adrenal cortical tumors from FAP
patients (Wakatsuki et al., 1998; Hosogi et al.,
2009; Gaujoux et al., 2010), the paucity of nu-
clear b-catenin staining in this patient’s adrenal
adenoma (Fig. 1D), coupled with the retention
of the wild-type APC allele (Fig. 3B) and the
absence of mutations in exon 3 of b-catenin in
the tumor (Fig. 4), suggest that somatic activa-
tion of Wnt signaling is not the basis for its
pathogenesis in this case. Somatic mutations in
other molecules and pathways that are associ-
ated with adrenal tumorigenesis, such as TP53
and insulin-like growth factor 2 signaling (Stra-
takis, 2003), may have played a role in its de-
velopment in this patient. Her germline APC
mutation may also have contributed to its
pathogenesis, as the incidence of adrenal ade-
noma in FAP patients is higher than that in
the general population (Marchesa et al., 1997;
Smith et al., 2000).
Ovarian steroid cell tumors account for less
than 0.1% of all ovarian tumors (Scully, 1979).
Virtually nothing is known about their pathoge-
nesis. Our demonstration of nuclear localization
of b-catenin and biallelic APC inactivation in
this tumor (Figs. 1 and 3) suggests that Wnt
pathway activation can lead to the development
of ovarian steroid cell tumors. The identiﬁcation
of activating b-catenin mutations in a signiﬁcant
percentage of sporadic tumors that are part of
the FAP neoplastic spectrum (Abraham et al.,
2001; Garcia-Rostan et al., 2001; Curia et al.,
2008; Lazar et al., 2008; Bonnet et al., 2011; Elli-
son et al., 2011) suggests that Wnt pathway acti-
vation may also contribute to tumorigenesis in at
least a subset of sporadic ovarian steroid cell
tumors.
Figure 4. b-catenin exon 3 sequences of PCR products ampliﬁed from genomic DNA. Codons
encoding conserved GSK-3b phosphorylation sites that mediate downregulation of b-catenin are
underlined.
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